<DOC>
	<DOCNO>NCT01122966</DOCNO>
	<brief_summary>The investigator plan evaluate additive effect intracameral subconjunctival injection bevacizumab trabeculectomies antimetabolite .</brief_summary>
	<brief_title>The Effect Bevacizumab Trabeculectomy</brief_title>
	<detailed_description>Glaucoma filtration surgery routinely utilized control intraocular pressure glaucomatous patient . It reduce IOP create fistula anterior chamber subconjunctival space filter bleb . Increased wound heal response affect function morphology filter bleb , wound heal involves series biological event begin hemostasis . Corticosteroids antifibrosis agent mitomycin C 5-fluorouracil employed trabeculectomy delay wound heal hence improve success rate surgery inhibit inflammation fibroblastic activity , use antiscarring agent generally believe improve success rate trabeculectomy.But rate decrease passing time thus perfect . Vascular endothelial growth factor pivotal stimulator angiogenesis bind VEGF receptor demonstrate promote endothelial cell migration proliferation wound healing.Therefore , anti-VEGF agent may potentially modulate wound heal follow glaucoma filtration surgery . The principal objective study evaluate additive effect intracameral subconjunctival injection bevacizumab trabeculectomy .</detailed_description>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>glaucoma patient trabeculectomy patient ocular disease</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>trabeculectomy</keyword>
</DOC>